Chang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chang Liu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Pengfei Li
Department of Thoracic Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
3 shared publications- Shu-Lan Sun
Central Laboratory, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China
2 shared publications - Chun-Ling Luo
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
1 shared publication - Chunyan Lan
Department of Gynecologic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, PR China
1 shared publication - Danbo Wang
Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China
1 shared publication Dapeng Li
Liaoning Promotion Center for the Transformation of Scientific and Technical Achievements, Liaoning Scientific and Technical Innovation Service Center, Shenyang, Liaoning Province, The People’s Republic of China
1 shared publication
Latest Publications
- 3 March 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 104 (1) , 133-134
Generalizability and implementation considerations for histopathologic evaluation of endoscopic ultrasound—guided fine-needle biopsy in solid pancreatic lesions
- 3 March 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 104 (1) , 133-134
Generalizability and implementation considerations for histopathologic evaluation of endoscopic ultrasound—guided fine-needle biopsy in solid pancreatic lesions
- 29 December 2025
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 103 (5) , 1096-1097
Navigating the gray zone: refining risk stratification after endoscopic resection for cervical esophageal squamous cell carcinoma
- 29 December 2025
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 103 (5) , 1096-1097
Navigating the gray zone: refining risk stratification after endoscopic resection for cervical esophageal squamous cell carcinoma
- Open Access
- 19 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1647988
Advances in the study of reversing tumor drug resistance by targeting cancer-associated fibroblasts with nanomaterials
Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment (TME) which promote drug resistance by remodeling the extracellular matrix, generating an immunosuppressive microenvironment, and activating metabolic signaling pathways. Nanomaterials provide an effective method for specifically targeting CAF-mediated drug resistance because of their unique targeted delivery capabilities, responsive release characteristics, and multifunctional integration. Here, we describe the mechanisms underlying the role of CAFs in drug resistance. The types of materials used and design principles are described, and examples of the application of nanomaterials for targeting CAFs are provided. Current challenges and future directions of nanomaterials targeting CAFs for reversing tumor drug resistance are also discussed to provide theoretical support for the development of effective nanotherapies aimed at reversing drug resistance in cancer.
- 19 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1647988
Open AccessAdvances in the study of reversing tumor drug resistance by targeting cancer-associated fibroblasts with nanomaterials
Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment (TME) which promote drug resistance by remodeling the extracellular matrix, generating an immunosuppressive microenvironment, and activating metabolic signaling pathways. Nanomaterials provide an effective method for specifically targeting CAF-mediated drug resistance because of their unique targeted delivery capabilities, responsive release characteristics, and multifunctional integration. Here, we describe the mechanisms underlying the role of CAFs in drug resistance. The types of materials used and design principles are described, and examples of the application of nanomaterials for targeting CAFs are provided. Current challenges and future directions of nanomaterials targeting CAFs for reversing tumor drug resistance are also discussed to provide theoretical support for the development of effective nanotherapies aimed at reversing drug resistance in cancer.
- 17 November 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (1) , 212-213
Beyond immune activation: unresolved questions in bepirovirsen’s mechanism of action toward HBV functional cure
- 17 November 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (1) , 212-213
Beyond immune activation: unresolved questions in bepirovirsen’s mechanism of action toward HBV functional cure
- 17 November 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (3) , 899-900
Cautious continuation: hepatic immune-related adverse events as a beacon for immune checkpoint inhibitor efficacy
- 17 November 2025
- Published by Springer Nature in Hepatology International
- Vol. 20 (3) , 899-900
Cautious continuation: hepatic immune-related adverse events as a beacon for immune checkpoint inhibitor efficacy
- 3 November 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (4) , 582-583
Letter: Optimizing Risk Stratification in Primary Biliary Cholangitis—The Role of Biochemical Response as a Dynamic Predictor
- 3 November 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (4) , 582-583
Letter: Optimizing Risk Stratification in Primary Biliary Cholangitis—The Role of Biochemical Response as a Dynamic Predictor
- Open Access
- 29 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 537-552
Elucidating the causal effects of plasma metabolites on breast cancer from multiple perspectives
Background: Early studies found common metabolic reprogramming in breast cancer. However, the causal effects of plasma metabolites on breast cancer remain unclear. Methods: Mendelian randomization (MR) and linkage disequilibrium score (LDSC) regression were performed based on previously published genome-wide association study (GWAS) summary statistics. The robustness of the causal inference was validated by sensitivity analyses. Gene mapping was performed by combining significant single-nucleotide polymorphisms (SNPs) and expression quantitative trait loci (eQTL) data to obtain the related gene set. Immune-related genes were identified by bulk and single-cell RNA analyses. Clinical samples were used for validation. Results: After correction and sensitivity analysis, seven significant plasma metabolites were identified. LDSC did not detect significant genetic correlations. Mapping SNPs to genes showed that two genes (SPP1 and ADM2) were significantly upregulated in breast cancer. However, only SPP1 passed external cohort validation. Similar results were obtained in the single-cell RNA analysis. In addition, SPP1 was found to be more highly expressed in monocytes. In clinical samples of breast cancer, we verified the high expression of SPP1 in monocytes–macrophages. At the cellular level, the high expression of SPP1 in monocytes–macrophages can promote malignant phenotypes such as proliferation and migration of breast cancer cells, and its expression level is regulated by myristic acid in significantly differential plasma metabolites. Conclusion: The findings provided valuable insight for the development of personalized treatment strategies for breast cancer and indicate that SPP1 may be a therapeutic target.
- 29 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 537-552
Open AccessElucidating the causal effects of plasma metabolites on breast cancer from multiple perspectives
Background: Early studies found common metabolic reprogramming in breast cancer. However, the causal effects of plasma metabolites on breast cancer remain unclear. Methods: Mendelian randomization (MR) and linkage disequilibrium score (LDSC) regression were performed based on previously published genome-wide association study (GWAS) summary statistics. The robustness of the causal inference was validated by sensitivity analyses. Gene mapping was performed by combining significant single-nucleotide polymorphisms (SNPs) and expression quantitative trait loci (eQTL) data to obtain the related gene set. Immune-related genes were identified by bulk and single-cell RNA analyses. Clinical samples were used for validation. Results: After correction and sensitivity analysis, seven significant plasma metabolites were identified. LDSC did not detect significant genetic correlations. Mapping SNPs to genes showed that two genes (SPP1 and ADM2) were significantly upregulated in breast cancer. However, only SPP1 passed external cohort validation. Similar results were obtained in the single-cell RNA analysis. In addition, SPP1 was found to be more highly expressed in monocytes. In clinical samples of breast cancer, we verified the high expression of SPP1 in monocytes–macrophages. At the cellular level, the high expression of SPP1 in monocytes–macrophages can promote malignant phenotypes such as proliferation and migration of breast cancer cells, and its expression level is regulated by myristic acid in significantly differential plasma metabolites. Conclusion: The findings provided valuable insight for the development of personalized treatment strategies for breast cancer and indicate that SPP1 may be a therapeutic target.
- Open Access
- 18 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (8)
Super-enhancer–driven EFNA1 fuels tumor progression in cervical cancer via the FOSL2-Src/AKT/STAT3 axis
Super-enhancers (SEs) are expansive cis -regulatory elements known for amplifying oncogene expression across various cancers. However, their role in cervical cancer (CC), a remarkable global malignancy affecting women, remains underexplored. Here we applied integrated epigenomic and transcriptomic profiling to delineate the distinct SE landscape in CC by analyzing paired tumor and normal tissues. Our study identifies a tumor-specific SE at the EFNA1 locus that drives EFNA1 expression in CC. Mechanically, the EFNA1-SE region contains consensus sequences for the transcription factor FOSL2, whose knockdown markedly suppressed luciferase activity and diminished H3K27ac enrichment within the SE region. Functional analyses further underlined EFNA1’s oncogenic role in CC, linking its overexpression to poor patient outcomes. EFNA1 knockdown strikingly reduced CC cell proliferation, migration, and tumor growth. Moreover, EFNA1 cis -interacted with its receptor EphA2, leading to decreased EphA2 tyrosine phosphorylation and subsequent activation of the Src/AKT/STAT3 forward signaling pathway. Inhibition of this pathway with specific inhibitors substantially attenuated the tumorigenic capacity of EFNA1-overexpressing CC cells in both in vitro and in vivo models. Collectively, our study unveils the critical role of SEs in promoting tumor progression through the FOSL2-EFNA1-EphA2-Src/AKT/STAT3 axis, providing new prognostic and therapeutic avenues for CC patients.
- 18 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (8)
Open AccessSuper-enhancer–driven EFNA1 fuels tumor progression in cervical cancer via the FOSL2-Src/AKT/STAT3 axis
Super-enhancers (SEs) are expansive cis -regulatory elements known for amplifying oncogene expression across various cancers. However, their role in cervical cancer (CC), a remarkable global malignancy affecting women, remains underexplored. Here we applied integrated epigenomic and transcriptomic profiling to delineate the distinct SE landscape in CC by analyzing paired tumor and normal tissues. Our study identifies a tumor-specific SE at the EFNA1 locus that drives EFNA1 expression in CC. Mechanically, the EFNA1-SE region contains consensus sequences for the transcription factor FOSL2, whose knockdown markedly suppressed luciferase activity and diminished H3K27ac enrichment within the SE region. Functional analyses further underlined EFNA1’s oncogenic role in CC, linking its overexpression to poor patient outcomes. EFNA1 knockdown strikingly reduced CC cell proliferation, migration, and tumor growth. Moreover, EFNA1 cis -interacted with its receptor EphA2, leading to decreased EphA2 tyrosine phosphorylation and subsequent activation of the Src/AKT/STAT3 forward signaling pathway. Inhibition of this pathway with specific inhibitors substantially attenuated the tumorigenic capacity of EFNA1-overexpressing CC cells in both in vitro and in vivo models. Collectively, our study unveils the critical role of SEs in promoting tumor progression through the FOSL2-EFNA1-EphA2-Src/AKT/STAT3 axis, providing new prognostic and therapeutic avenues for CC patients.
- 25 September 2024
- Published by Elsevier in Environmental Research
- Vol. 263 (Pt 2) , 119928
The association between ambient PM2.5's constituents exposure and cervical cancer survival
- 25 September 2024
- Published by Elsevier in Environmental Research
- Vol. 263 (Pt 2) , 119928
The association between ambient PM2.5's constituents exposure and cervical cancer survival